Prognostic factors in patients with high-risk stage II colon cancer after curative resection: a post hoc analysis of the JFMC46-1201 trial
Kiichi Sugimoto(Juntendo University), Sotaro Sadahiro(Tokai University), Kazuhiro Sakamoto(Juntendo University), Hiroki Ohge(Hiroshima University Hospital), Takao Takahashi(Maruyama Memorial General Hospital), Satoshi Morita(Kyoto University), Takashi Tsuchiya(Sendai Medical Center), Toshihiko Satō(Yamagata Prefectural Central Hospital), Masataka Taguri(Yokohama City University)
Cited by 10
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
The cell cycle of the pseudostratified ventricular epithelium of the embryonic murine cerebral wall
|Journal of Neuroscience|1995|672
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
|The Lancet Oncology|2019|642